Abstract
BACKGROUND: Poa pratensis is a predominant cool-season turfgrass utilized in urban landscaping and ecological management. It is extensively employed in turf construction and in the regulation of ecological environments. However, it is susceptible to powdery mildew, a prevalent disease in humid regions. Currently, the primary control measure for powdery mildew involves the application of pesticides, a practice that is both costly and environmentally detrimental. Developing superior disease-resistant cultivars represents a more cost-effective and sustainable strategy for managing turfgrass diseases. Furthermore, an in-depth investigation into the response mechanisms of P. pratensis to powdery mildew infection could significantly advance research on the identification of disease resistance genes and the molecular breeding of resistant varieties. RESULTS: In this study, we first assessed the disease incidence across various disease-resistant P. pratensis cultivars and subsequently examined alterations in their in vivo redox states. We employed isobaric tags for relative and absolute quantification (iTRAQ) proteomics alongside non-targeted metabolomics to elucidate the response mechanisms of P. pratensis to powdery mildew invasion. A comprehensive analysis of the shared KEGG pathways among differentially abundant proteins (DAPs) and differentially enriched metabolites (DEMs) led to the identification of four common KEGG pathways. Notably, the phenylpropanoid biosynthesis pathway, enriched in both examined P. pratensis cultivars, was selected for further investigation. This analysis indicated that lignin biosynthesis plays a crucial role in the response of P. pratensis to powdery mildew infection. CONCLUSIONS: The findings of this study enhance our understanding of the mechanisms underlying powdery mildew resistance in P. pratensis and serve as a valuable reference for the selection of powdery mildew-resistant cultivars, as well as for the identification and application of associated disease resistance genes. CLINICAL TRIAL NUMBER: Not applicable.